{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:29:03Z","timestamp":1790832543868,"version":"4.1.0"},"reference-count":148,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The game-changing outcome effect, due to the generalized use of novel agents in MM, has cre-ated a paradigm shift. Achieving frequent deep responses has placed MM among those neoplasms where the rationale for assessing MRD is fulfilled. However, its implementation in MM has raised specific questions: how might we weight standard measures against deep MRD in the emerging CAR-T setting? Which high sensitivity method to choose? Are current response criteria still useful? In this work, we address lessons learned from the use of MRD in other neoplasms, the steps followed for the harmonization of current methods for comprehensively measuring MRD, and the challenges that new therapies and concepts pose in the MM clinical field.<\/jats:p>","DOI":"10.3390\/cancers13174332","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T09:53:23Z","timestamp":1630058003000},"page":"4332","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Minimal Residual Disease in Multiple Myeloma: Something Old, Something New"],"prefix":"10.3390","volume":"13","author":[{"given":"Carlos","family":"Bravo-P\u00e9rez","sequence":"first","affiliation":[{"name":"Hematology and Medical Oncology Department, University Hospital Morales Meseguer, IMIB, 30003 Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Sola","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology Department, University Hospital Morales Meseguer, IMIB, 30003 Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Teruel-Montoya","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology Department, University Hospital Morales Meseguer, IMIB, 30003 Murcia, Spain"},{"name":"CB15\/00055-CIBERER, 30003 Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Garc\u00eda-Malo","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology Department, University Hospital Morales Meseguer, IMIB, 30003 Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jos\u00e9","family":"Ortu\u00f1o","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology Department, University Hospital Morales Meseguer, IMIB, 30003 Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4278-3264","authenticated-orcid":false,"given":"Vicente","family":"Vicente","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology Department, University Hospital Morales Meseguer, IMIB, 30003 Murcia, Spain"},{"name":"CB15\/00055-CIBERER, 30003 Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"de Arriba","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology Department, University Hospital Morales Meseguer, IMIB, 30003 Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Jerez","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology Department, University Hospital Morales Meseguer, IMIB, 30003 Murcia, Spain"},{"name":"CB15\/00055-CIBERER, 30003 Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","article-title":"Dramatically improved survival in multiple myeloma patients in the recent decade: Results from a Swedish population-based study","volume":"103","author":"Thorsteinsdottir","year":"2018","journal-title":"Haematologica"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Zabell, J. (2021). Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer. 50 Studies Every Urologist Should Know, Oxford University Press.","DOI":"10.1093\/med\/9780190655341.003.0015"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1158\/1078-0432.CCR-16-2895","article-title":"The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications","volume":"23","author":"Anderson","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrc.2017.125","article-title":"Targeting Minimal Residual Disease: A Path to Cure?","volume":"18","author":"Luskin","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","first-page":"1307","article-title":"Something old, something new\u2026","volume":"135","author":"Stevens","year":"2020","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMe1009141","article-title":"Management of Immune Thrombocytopenia\u2014Something Old, Something New","volume":"363","author":"George","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1182\/asheducation-2009.1.656","article-title":"Treatment of MDS: Something old, something new, something borrowed","volume":"2009","author":"Sekeres","year":"2009","journal-title":"Hematology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1200\/JCO.1993.11.10.1879","article-title":"The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03","volume":"11","author":"Wolmark","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V26.5.642.642","article-title":"The Effectiveness of Combinations of Antileukemic Agents in Inducing and Maintaining Remission in Children with Acute Leukemia","volume":"26","author":"Frei","year":"1965","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","article-title":"Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group","volume":"34","author":"Pieters","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: The NEXT-in-CML study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1200\/JCO.2013.49.0086","article-title":"Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma","volume":"31","author":"Kapoor","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: A meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of Minimal Residual Disease with Superior Survival Outcomes in Patients with Multiple Myeloma","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/asheducation-2017.1.205","article-title":"Is molecular remission the goal of multiple myeloma therapy?","volume":"2017","author":"Davies","year":"2017","journal-title":"Hematology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2019.37.15_suppl.8002","article-title":"Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial","volume":"37","author":"Gay","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: A meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1016\/j.clml.2019.09.308","article-title":"Minimal residual disease assessment using EuroFlow in patients with relapsed\/refractory multiple myeloma who received carfilzomib+lenalidomide+dexamethasone (KRD) therapy","volume":"19","author":"Takamatsu","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2001-12-0297","article-title":"Flow cytometric disease monitoring in multiple myeloma: The relationship between normal and neoplastic plasma cells predicts outcome after transplantation","volume":"100","author":"Rawstron","year":"2002","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood-2014-05-573733","article-title":"GEM2005 trial update comparing VMP\/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?","volume":"124","author":"Oriol","year":"2014","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1038\/bcj.2014.69","article-title":"Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma","volume":"4","author":"Silvennoinen","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.3324\/haematol.2014.115162","article-title":"The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma","volume":"100","author":"Paiva","year":"2014","journal-title":"Haematologica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/bjh.13582","article-title":"Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up","volume":"171","author":"Ludwig","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/blood.V128.22.4508.4508","article-title":"Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood.V128.22.245.245","article-title":"Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial","volume":"128","author":"Rawstron","year":"2016","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428194.2015.1121262","article-title":"Prognostic impact of immunophenotypic complete response in patients with multiple myeloma achieving better than complete response","volume":"57","author":"Fukumoto","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_35","first-page":"531","article-title":"Maintenance Therapy with Bortezomib in Patients with Multiple Myeloma (MM) after ASCT and Minimal Residual Disease (MRD)","volume":"102","author":"Solovev","year":"2017","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Paiva","year":"2017","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.bbmt.2017.01.076","article-title":"Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics","volume":"23","author":"Chakraborty","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_38","first-page":"1864","article-title":"Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)","volume":"130","author":"Popat","year":"2017","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00498-0","article-title":"Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial","volume":"11","author":"Oliva","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_40","first-page":"2018","article-title":"Sustained MRD Negativity at 12 Months Post-ASCT Predicts Outcomes for Myeloma Patients: A Real World Study","volume":"215626","author":"Austin","year":"2018","journal-title":"EHA Library"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/s41409-018-0241-2","article-title":"Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy","volume":"53","author":"Clark","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1016\/j.bbmt.2018.07.040","article-title":"Longitudinal Flow Cytometry Identified \u201cMinimal Residual Disease\u201d (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma","volume":"24","author":"Gu","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood-2018-99-116426","article-title":"Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease","volume":"132","author":"Yong","year":"2018","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1182\/blood-2018-99-116014","article-title":"Depth of Response and Outcomes in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1182\/blood-2018-99-112790","article-title":"Efficacy of Maintenance Therapy Following Auto-HSCT Depending on MRD Status in Patients with Multiple Myeloma","volume":"132","author":"Solovev","year":"2018","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","article-title":"Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"133","author":"Facon","year":"2019","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1200\/JCO.2019.37.15_suppl.8003","article-title":"Efficacy of daratumumab (DARA) + bortezomib\/thalidomide\/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial","volume":"37","author":"Moreau","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00277-019-03609-x","article-title":"Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: A retrospective single-center analysis","volume":"98","author":"Li","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/cyto.b.21755","article-title":"Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma","volume":"96","author":"Rossi","year":"2018","journal-title":"Cytom. Part. B Clin. Cytom."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.bbmt.2018.12.687","article-title":"Minimal Residual Disease (MRD) Assessment before and after Autologous Hematopoietic Cell Transplantation (AutoHCT) and Maintenance for Multiple Myeloma (MM): Results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study","volume":"25","author":"Hahn","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2018","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ajh.25507","article-title":"Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma","volume":"94","author":"Alonso","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1046\/j.1365-2141.1998.01075.x","article-title":"Clinical utility of immunoglobulin heavy chain gene rearrangement identification for tumour cell detection in multiple myeloma","volume":"103","author":"Swedin","year":"1998","journal-title":"Br. J. Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2141.2004.05120.x","article-title":"Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma","volume":"126","author":"Bakkus","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1365-2141.2008.07263.x","article-title":"Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: The prognostic impact of achieving molecular response","volume":"142","author":"Montejano","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1600-0609.2010.01510.x","article-title":"Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma","volume":"85","author":"Putkonen","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bbmt.2011.07.002","article-title":"The Level of Minimal Residual Disease in the Bone Marrow of Patients with Multiple Myeloma before High-Dose Therapy and Autologous Blood Stem Cell Transplantation Is an Independent Predictive Parameter","volume":"18","author":"Korthals","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2014.219","article-title":"Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics\u2019 impact on survival","volume":"29","author":"Ferrero","year":"2014","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/cncr.31854","article-title":"Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis","volume":"125","author":"Gambella","year":"2018","journal-title":"Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1182\/blood.V128.22.3283.3283","article-title":"Prognostic Impact of Molecular Response Assessed by Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients","volume":"128","author":"Alonso","year":"2016","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.3324\/haematol.2017.165217","article-title":"The Prognostic Value of the Depth of Response in Multiple Myeloma Depends on the Time of Assessment, Risk Status and Molecular Subtype","volume":"102","author":"Schinke","year":"2017","journal-title":"Haematologica"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2017.58","article-title":"Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma","volume":"31","author":"Barrio","year":"2017","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood-2018-99-113177","article-title":"Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed\/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor","volume":"132","author":"Casneuf","year":"2018","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2019-123426","article-title":"Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia","volume":"134","author":"Bahlis","year":"2019","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: Back to the future","volume":"131","author":"Richardson","year":"2018","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","article-title":"Treatment Options for Triple-class Refractory Multiple Myeloma","volume":"20","author":"Mikhael","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Radocha, J., van de Donk, N., and Weisel, K. (2021). Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13071571"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Zhou, X., Einsele, H., and Danhof, S. (2020). Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072166"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/PPO.0000000000000413","article-title":"Relevance of Minimal R W.; Du, J.; Jiang, H.; Cheng, Z.; Wei, R. Esidual Disease in the Era of Targeted Agents","volume":"25","author":"Heltai","year":"2019","journal-title":"Cancer J."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Kostopoulos, I., Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Tsitsilonis, O.E., and Terpos, E. (2020). Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications with Immunotherapeutic Approaches. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00860"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1182\/bloodadvances.2020004017","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: A systematic review and meta-analysis of 950 patients","volume":"5","author":"Mohyuddin","year":"2021","journal-title":"Blood Adv."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti\u2013B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood-2019-130341","article-title":"Potent Anti-Tumor Activity of Bcma CAR-T Therapy Against Heavily Treated Multiple Myeloma and Dynamics of Immune Cell Subsets Using Single-Cell Mass Cytometry","volume":"134","author":"Hu","year":"2019","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1182\/blood-2019-130340","article-title":"A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed\/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood-2019-131515","article-title":"Combination anti-BCMA and anti-CD19 CAR T cells as consolidation of response to prior therapy in multiple myeloma","volume":"134","author":"Garfall","year":"2019","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2019-124953","article-title":"Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2019-127608","article-title":"Efficacy and Safety of CAR-T Therapy with Safety Switch Targeting Bcma for Patients with Relapsed\/Refractory Multiple Myeloma in a Phase 1 Clinical Study","volume":"134","author":"Fu","year":"2019","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2019-129405","article-title":"Efficacy and safety of fully human BCMA CAR T cells in combination with a gamma secretase inhibitor to increase BCMA surface expression in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Cowan","year":"2019","journal-title":"Blood"},{"key":"ref_90","first-page":"26","article-title":"Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study","volume":"136","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-140156","article-title":"Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells (CT053) in Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Hao","year":"2020","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-136307","article-title":"CARTITUDE-1: Phase 1b\/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-139802","article-title":"Results from Lummicar-2: A Phase 1b\/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and\/or Refractory Multiple Myeloma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"ref_94","first-page":"25","article-title":"Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1200\/JCO.20.01814","article-title":"Evaluation of Sustained Minimal Residual Disease Negativity with Daratumumab-Combination Regimens in Relapsed and\/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR","volume":"39","author":"Casneuf","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cyto.b.21271","article-title":"Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service","volume":"90","author":"Rawstron","year":"2015","journal-title":"Cytom. Part. B Clin. Cytom."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","article-title":"Minimal residual disease in multiple myeloma: Bringing the bench to the bedside","volume":"12","author":"Mailankody","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_98","first-page":"61","article-title":"Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Paiva","year":"2015","journal-title":"Cytom. Part. B Clin. Cytom."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA\/GEM Clinical Trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1038\/bcj.2013.33","article-title":"A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma","volume":"3","author":"Robillard","year":"2013","journal-title":"Blood Cancer J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.3324\/haematol.2020.267831","article-title":"Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network","volume":"106","author":"Bruinink","year":"2020","journal-title":"Haematologica"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: Comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/ajcp\/aqw052","article-title":"Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma","volume":"146","author":"Royston","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/ajh.23831","article-title":"Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium","volume":"89","author":"Landgren","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/cyto.b.21276","article-title":"Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma","volume":"90","author":"Oldaker","year":"2015","journal-title":"Cytom. Part. B Clin. Cytom."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-89761-9","article-title":"Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods","volume":"11","author":"Yoroidaka","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/blood-2019-130607","article-title":"Comparison of the Performance of Surface Alone or Surface Plus Cytoplasmic Approaches for the Assessment of Minimal Residual Disease in Multiparameter Flow Cytometry in Multiple Myeloma","volume":"134","author":"Bene","year":"2019","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.3324\/haematol.2019.238394","article-title":"Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma","volume":"105","author":"Dold","year":"2020","journal-title":"Haematologica"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/ijlh.12365","article-title":"ICSH guidelines for the standardization of bone marrow immunohistochemistry","volume":"37","author":"Torlakovic","year":"2015","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2020","journal-title":"Leukemia"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"(2018). ClonoSEQ Cleared for Residual Cancer Testing. Cancer Discov., 8, OF6.","DOI":"10.1158\/2159-8290.CD-NB2018-136"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/leu.2012.246","article-title":"EuroClonality\/BIOMED-2 guidelines for interpretation and reporting of Ig\/TCR clonality testing in suspected lymphoproliferations","volume":"26","author":"Langerak","year":"2012","journal-title":"Leukemia"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2013.217","article-title":"Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry","volume":"28","author":"Puig","year":"2013","journal-title":"Leukemia"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Lahuerta","year":"2014","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-134847","article-title":"Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1038\/bcj.2017.78","article-title":"Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: A study of the International Myeloma Working Group","volume":"7","author":"Hillengass","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3109\/10428194.2016.1143941","article-title":"Myeloma imaging: Time to move on!","volume":"57","author":"Manasanch","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_121","first-page":"137","article-title":"What to do with minimal residual disease testing in myeloma","volume":"2019","author":"Manasanch","year":"2019","journal-title":"Hematol. 2014 Am. Soc. Hematol. Program. Book"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications","volume":"25","author":"Walker","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Jamet, B., Zamagni, E., Nanni, C., Bailly, C., Carlier, T., Touzeau, C., Michaud, A.-V., Moreau, P., Bodet-Milin, C., and Kraeber-Bodere, F. (2020). Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155406"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.13509","article-title":"Whole body diffusion weighted MRI\u2014A new view of myeloma","volume":"171","author":"Messiou","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Zamagni, E., Tacchetti, P., Barbato, S., and Cavo, M. (2020). Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113519"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-135969","article-title":"External Validation of Diffusion Weighted Whole Body MRI (DW-MRI) Response Assessment Category (RAC) Criteria Proposed By the Myeloma Response Assessment and Diagnosis System (MY-RADS) Imaging Recommendations: Prognostic Role of Imaging Response after Transplant in Multiple Myeloma and Comparison with MRD Evaluation by Flow Cytometry","volume":"136","author":"Belotti","year":"2020","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.critrevonc.2018.02.012","article-title":"Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or 18 F-fluorodeoxyglucose positron emission tomography\/CT (18 F-FDG PET\/CT) in patients with myeloma: Systematic review of diagnostic performance","volume":"124","author":"Gariani","year":"2018","journal-title":"Crit. Rev. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","article-title":"Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM\/DFCI 2009 Trial: Results of the IMAJEM Study","volume":"35","author":"Moreau","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Rasch, S., Lund, T., Asmussen, J., Nielsen, A.L., Larsen, R.F., Andersen, M., and Abildgaard, N. (2020). Multiple Myeloma Associated Bone Disease. Cancers, 12.","DOI":"10.20944\/preprints202007.0041.v1"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2967\/jnumed.114.151647","article-title":"Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe 68Ga-Pentixafor","volume":"56","author":"Herrmann","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.seminhematol.2018.02.009","article-title":"Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods","volume":"55","year":"2018","journal-title":"Semin. Hematol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Ogawa, M., Yokoyama, K., Imoto, S., and Tojo, A. (2021). Role of Circulating Tumor DNA in Hematological Malignancy. Cancers, 13.","DOI":"10.3390\/cancers13092078"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy","volume":"134","author":"Puig","year":"2019","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/bloodadvances.2018025197","article-title":"Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow","volume":"2","author":"Mazzotti","year":"2018","journal-title":"Blood Adv."},{"key":"ref_139","first-page":"1","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Paiva","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1038\/leu.2016.366","article-title":"Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma","volume":"31","author":"Mithraprabhu","year":"2016","journal-title":"Leukemia"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-04001-5","article-title":"Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma","volume":"9","author":"Manier","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1038\/s41375-019-0469-x","article-title":"Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients","volume":"33","author":"Mithraprabhu","year":"2019","journal-title":"Leukemia"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Mithraprabhu, S., Sirdesai, S., Chen, M., Khong, T., and Spencer, A. (2018). Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19071858"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e19529","DOI":"10.1200\/JCO.2019.37.15_suppl.e19529","article-title":"Cost-effectiveness of next-generation sequencing minimal residual disease testing during maintenance treatment for multiple myeloma","volume":"37","author":"Carlson","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-143234","article-title":"Cost-Effectiveness of Implementing Clonoseq NGS-MRD Testing Using the Emory MRD Decision Protocol in Multiple Myeloma","volume":"136","author":"Carlson","year":"2020","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2020.38.15_suppl.8503","article-title":"Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results","volume":"38","author":"Munshi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1002\/acg2.26","article-title":"Meeting report: Advances in minimal residual disease testing in multiple myeloma","volume":"2","author":"Landgren","year":"2018","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_148","unstructured":"Ubieto, A.J., Paiva, B., Puig, N., Cedena, M.-T., Martinez-Lopez, J., Oriol, A., Blanchard, M.-J., Tamayo, R.R., S\u00e1nchez, J.M., and Martinez, R. (2021). Validation of the IMWG standard response criteria in the PETHEMA\/GEM2012MENOS65 study: Are these times of change?. Blood."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/17\/4332\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:53:26Z","timestamp":1760165606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/17\/4332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":148,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["cancers13174332"],"URL":"https:\/\/doi.org\/10.3390\/cancers13174332","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,27]]}}}